The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer

Background. Thirty to forty percent of patients with high grade nonmuscle invasive bladder cancer (NMIBC) fail to respond to intravesical therapy with bacillus Calmette-Guerin (BCG). Interferon-α2B plus BCG has been shown to be effective in a subset of patients with NMIBC BCG refractory disease. Her...

Descripción completa

Detalles Bibliográficos
Autores principales: Correa, Andres F., Theisen, Katherine, Ferroni, Matthew, Maranchie, Jodi K., Hrebinko, Ronald, Davies, Benjamin J., Gingrich, Jeffrey R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621325/
https://www.ncbi.nlm.nih.gov/pubmed/26550012
http://dx.doi.org/10.1155/2015/656918

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621325/
https://www.ncbi.nlm.nih.gov/pubmed/26550012
http://dx.doi.org/10.1155/2015/656918

Ejemplares similares